Combination Therapy with Renin-Angiotensin System Inhibitors and the Calcium Channel Blocker Azelnidipine Decreases Plasma Inflammatory Markers and Urinary Oxidative Stress Markers in Patients with Diabetic Nephropathy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Hypertension Research

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1291/hypres.31.1147PMID 18716362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation

  2008cited by this paper
• Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan.

  2007cited by this paper
• Chronic ethanol-induced insulin resistance is associated with macrophage infiltration into adipose tissue and altered expression of adipocytokines.

  2007cited by this paper
• Indapamide Decreases Plasma Adiponectin Concentration in Patients with Essential Hypertension

  2007cited by this paper
• Azelnidipine Reduces Urinary Protein Excretion and Urinary Liver-Type Fatty Acid Binding Protein in Patients with Hypertensive Chronic Kidney Disease

  2007influential reference
• Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis

  2007cited by this paper
• Diet-Induced Increases in Adiposity, but Not Plasma Lipids, Promote Macrophage Infiltration Into White Adipose Tissue

  2007cited by this paper
• Azelnidipine Inhibits H2O2-Induced Cell Death in Neonatal Rat Cardiomyocytes

  2007cited by this paper
• Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

  2007cited by this paper
• Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes.

  2007cited by this paper
• Long-Acting Calcium Channel Blocker, Azelnidipine, Increases Endothelial Nitric Oxide Synthase in the Brain and Inhibits Sympathetic Nerve Activity

  2007cited by this paper
• Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.

  2007cited by this paper
• Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome

  2007cited by this paper
• Effects of Monotherapy of Temocapril or Candesartan with Dose Increments or Combination Therapy with Both Drugs on the Suppression of Diabetic Nephropathy

  2007cited by this paper
• Efficacy of Azelnidipine on Home Blood Pressure and Pulse Rate in Patients with Essential Hypertension: Comparison with Amlodipine

  2006cited by this paper
• Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.

  2006cited by this paper
• The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension.

  2006cited by this paper
• Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance*

  2006cited by this paper
• Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.

  2006cited by this paper
• Azelnidipine, a New Long-acting Calcium-channel Blocker, Inhibits Tumour Necrosis Factor-α-induced Monocyte Chemoattractant Protein-1 Expression in Endothelial Cells

  2006influential reference
• Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome.

  2006cited by this paper
• The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage

  2006cited by this paper
• Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy

  2006cited by this paper
• Effects of Calcium Channel Blockade on Angiotensin II-Induced Peritubular Ischemia in Rats

  2006cited by this paper
• Effects of a New Calcium Channel Blocker, Azelnidipine, on Systemic Hemodynamics and Renal Sympathetic Nerve Activity in Spontaneously Hypertensive Rats

  2005cited by this paper
• Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice

  2005cited by this paper
• Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.

  2005cited by this paper
• Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.

  2005cited by this paper
• Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.

  2005cited by this paper
• Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan

  2004influential reference
• Calcium Channel Blocker Azelnidipine Enhances Vascular Protective Effects of AT1 Receptor Blocker Olmesartan

  2004cited by this paper
• Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells.

  2004cited by this paper
• Pharmacological aspects of calcium channel blockers

  2004cited by this paper
• Azelnidipine, A Newly Developed Long-Acting Calcium Antagonist, Inhibits Tumor Necrosis Factor-&agr;-Induced Interleukin-8 Expression in Endothelial Cells through its Anti-Oxidative Properties

  2004cited by this paper
• Antioxidant Effect of a New Calcium Antagonist, Azelnidipine, in Cultured Human Arterial Endothelial Cells

  2004cited by this paper
• Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.

  2004cited by this paper
• Molecular motors

  2003cited by this paper
• Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension

  2003cited by this paper
• Reactive oxygen species in the vasculature: molecular and cellular mechanisms.

  2003cited by this paper
• Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity

  2002cited by this paper
• Molecular understanding of hyperglycemia's adverse effects for diabetic complications.

  2002cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.

  2002cited by this paper
• SYMPATHETIC NERVOUS SYSTEM, DIABETES, AND HYPERTENSION

  2001cited by this paper
• Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy

  1999cited by this paper
• Is the circulating ouabain-like compound ouabain?

  1994cited by this paper
• Effects of CS-905, a novel dihydropyridine calcium channel blocker, on arterial pressure, renal excretory function, and inner medullary blood flow in the rat.

  1994cited by this paper
• Nicardipine causes sympathetic activation that does not involve baroreceptor reflex tachycardia in conscious sinoaortic-denervated dogs.

  1987cited by this paper

• Hypothyroid women have persistently higher oxidative stress compared to healthy controls

  2023cites this paper
• N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis

  2023cites this paper
• Potential protective effects of Azelnidipine against cerebral ischemia-reperfusion injury in male rats

  2022cites this paper
• Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review

  2022cites this paper
• Brief overview of diabete mellitus

  2021cites this paper
• An Indole-2-Carboxamide Derivative, LG4, Alleviates Diabetic Kidney Disease Through Inhibiting MAPK-Mediated Inflammatory Responses

  2021influential citation
• Commentary: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 Statement: What Neurosurgeons Should Know.

  2021influential citation
• Association of Serum PSP/REG Iα with Renal Function in Type 2 Diabetes Mellitus

  2020cites this paper
• Diabetic nephropathy: A short review

  2020cites this paper
• Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress.

  2019cites this paper
• Interventions targeted at oxidatively generated modifications of nucleic acids focused on urine and plasma markers.

  2019cites this paper
• Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

  2019cites this paper
• Innate immune response in the pathogenesis of heart failure in survivors of myocardial infarction.

  2019cites this paper
• Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril

  2017cites this paper
• Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders

  2015cites this paper
• Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis

  2015cites this paper
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)

  2014cites this paper
• Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.

  2014cites this paper
• Association between urinary 8-OHdG and pulse wave velocity in hypertensive patients with type 2 diabetes mellitus.

  2014cites this paper
• Effects of Combination Therapy With Olmesartan and Azelnidipine on Serum Osteoprotegerin in Patients With Hypertension

  2014cites this paper
• Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial.

  2013cites this paper
• Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.

  2013cites this paper
• Biomarkers and assessment of drug efficacy in cardiovascular disease

  2013cites this paper
• The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: The OLCA study

  2012cites this paper
• Association of Oxidative DNA Damage and C-Reactive Protein in Women at Risk for Cardiovascular Disease

  2012cites this paper
• Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells

  2012cites this paper
• Off-target effects of RAAS-inhibition

  2012cites this paper
• Off-target effects of RAAS-inhibition: importance on renal outcomes in patients with diabetes

  2012cites this paper
• Effect of erythropoietin-stimulating agent on uremic inflammation

  2012cites this paper
• Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.

  2011cites this paper
• Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes.

  2011cites this paper
• Suppressive Effects of Valsartan on Microalbuminuria and CRP in Patients with Metabolic Syndrome (Val-Mets)

  2011cites this paper
• Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate

  2011cites this paper
• Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function - a crossover trial (AGENT)

  2011cites this paper
• Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes.

  2011cites this paper
• Urinary 8‐hydroxy‐2′‐deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure

  2011cites this paper
• L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers

  2011cites this paper
• Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria

  2011cites this paper
• Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.

  2011cites this paper
• Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG)

  2011influential citation
• Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.

  2010cites this paper
• Combination Therapy of Calcium Channel Blocker and Angiotensin II Receptor Blocker Reduces Augmentation Index in Hypertensive Patients

  2010cites this paper
• Inflammation and Therapy for Hypertension

  2010cites this paper
• T-type Ca channel blockade as a determinant of kidney protection.

  2010cites this paper
• Influencing factors for dietary behaviors of patients with diabetic nephropathy.

  2010cites this paper
• Peroxynitrite mediates glomerular lesion of diabetic rat via JAK/STAT signaling pathway.

  2009cites this paper
• Irbesartan‐mediated reduction of renal and cardiac damage in insulin resistant JCR : LA‐cp rats

  2009cites this paper
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)

  2009cites this paper
• Peroxynitrite mediates glomerular lesion of diabetic rat via JAK/STAT signaling pathway

  2009cites this paper
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).

  2009cites this paper
• Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension

  2009cites this paper
• A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study

  2009cites this paper